RVL Pharmaceuticals PLC RVLPQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.97
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $111.41
- Volume/Avg
- 14,157 / 71,558
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 127
- Website
- https://www.rvlpharma.com
Comparables
Valuation
|
Metric
|
RVLPQ
|
ZURA
|
GHRS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.00 | 2.66 | 2.50 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RVLPQ
ZURA
GHRS
Financial Strength
|
Metric
|
RVLPQ
|
ZURA
|
GHRS
|
|---|---|---|---|
Quick Ratio | 0.31 | 4.92 | 24.14 |
Current Ratio | 0.38 | 4.97 | 24.49 |
Interest Coverage | −5.28 | — | −706.38 |
Quick Ratio
RVLPQ
ZURA
GHRS
Profitability
|
Metric
|
RVLPQ
|
ZURA
|
GHRS
|
|---|---|---|---|
Return on Assets (Normalized) | −35.96% | −71.08% | −12.75% |
Return on Equity (Normalized) | −92.82% | −139.85% | −13.12% |
Return on Invested Capital (Normalized) | −34.43% | −99.89% | −16.87% |
Return on Assets
RVLPQ
ZURA
GHRS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qffrbrqsm | Znq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ycrmjtjv | Fpjht | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bzdgpgmry | Qvqqlyw | $97.8 Bil | |
MRNA
| Moderna Inc | Sgbgfrxj | Zpwj | $41.3 Bil | |
ARGX
| argenx SE ADR | Ttqtgdgk | Ccdgk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Hwjnhmrx | Dchvy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kcndgcsqb | Qrclf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pqqqmdk | Rqydnz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lsqdnrgb | Npjbr | $12.5 Bil | |
INCY
| Incyte Corp | Zxqrzrdtg | Hbgvt | $11.6 Bil |